Optimizing Dendritic Cell Cancer Vaccine Efficacy with InfinixBio

InfinixBio supported the development of a Dendritic Cell Cancer Vaccine, focusing on methods to ensure the potency and effectiveness of activated Dendritic Cells stimulated with patient-derived tumor cells.

Client’s Goals:

The goal was to enhance their Dendritic Cell Vaccine technology through clinical trials to improve treatment efficacy for cancer patients.

Challenges Faced:

The project demanded expertise in:

Manipulating and analyzing complex Dendritic cell samples.
Handling human-derived Peripheral Blood Mononuclear Cells (PBMCs).
Analyzing differentiated cell populations and tumor-specific cell killing.

Solutions Provided by InfinixBio:

Our team developed several key assays:

Cell-based assays for proper Dendritic Cell activation.
Methods for quantifying immune cell differentiation and expansion.
ELISpot assays to measure cytotoxic T cell activation.
Demonstrated effective cancer cell elimination by immune cells.
Established methodologies for clinical trial effectiveness.

Results:

Our methods enabled the client to progress their cancer vaccine technology through clinical trials, expanding its application to various types of cancer, and offering new treatment possibilities.